Evidence map›Paper›PMID 34769444›Full record

ArticleInternational journal of molecular sciences2021

Affibody Functionalized Beads for the Highly Sensitive Detection of Cancer Cell-Derived Exosomes.

Nima Sayyadi, Sareh Zhand, Sajad Razavi Bazaz, Majid Ebrahimi Warkiani

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Biomimetic behaviors in hydrogel artificial cells through embedded organelles.Proceedings of the National Academy of Sciences of the United States of America · 2023
    Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 2 countries.

Nima SayyadiDepartment of Biomedical Sciences, Faculty of Medicine and Health Science, Macquarie University, Sydney, NSW 2109, Australia.ORCID 0000-0002-0044-2170
Sareh ZhandSchool of Biomedical Engineering, University of Technology Sydney, Sydney, NSW 2007, Australia.
Sajad Razavi BazazSchool of Biomedical Engineering, University of Technology Sydney, Sydney, NSW 2007, Australia.ORCID 0000-0002-6419-3361
Majid Ebrahimi WarkianiSchool of Biomedical Engineering, University of Technology Sydney, Sydney, NSW 2007, Australia.
University of Technology Sydney · AU

Funding

ARC Centre of Excellence for Nanoscale BioPhotonics CE140100003Australian Research Council DP170103704, DP180103003NHMRC APP1143377
6 · The paper itself

Abstract

Exosomes belong to the class of extracellular vesicles of endocytic origin, which are regarded as a promising source of cancer biomarkers in liquid biopsy. As a result, an accurate, sensitive, and specific quantification of these nano-sized particles is of significant importance. Affinity-based approaches are recognized as the most valuable technique for exosome isolation and characterization. Indeed, Affibody biomolecules are a type of protein scaffold engineered with small size and enjoy the features of high thermal stability, affinity, and specificity. While the utilization of antibodies, aptamers, and other biologically active substances for exosome detection has been reported widely, there are no reports describing Affibody molecules' usage for exosome detection. In this study, for the first time, we have proposed a novel strategy of using Affibody functionalized microbeads (AffiBeads) for exosome detection with a high degree of efficiency. As a proof-of-concept, anti-EGFR-AffiBeads were fabricated and applied to capture and detect human lung A549 cancer cell-derived EGFR-positive exosomes using flow cytometry and fluorescent microscopy. Moreover, the capture efficiency of the AffiBeads were compared with its counterpart antibody. Our results showed that the Affibody probe had a detection limit of 15.6 ng exosomes per mL (~12 exosomes per AffiBead). The approach proposed in the current study can be used for sensitive detection of low expression level markers on tumor-derived exosomes, providing a basis for early-stage cancer diagnosis.

Indexed as

Antibodies, MonoclonalBiomarkers, TumorCell Line, TumorEarly Detection of CancerErbB ReceptorsExosomesExtracellular VesiclesHumansLiquid BiopsyNeoplasmsAntibodies, MonoclonalBiomarkers, TumorEGFR protein, humanErbB ReceptorsAffibodycancer-derived exosomeexosome biomarker

Identifiers

PMID34769444
PMCPMC8584739
OpenAlexW3211705432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.